MAPT and tauopathy: The treatment of transgenic mice with Thiamet-G, an OGA inhibitor, results in increased brain O-GlcNAc levels, and alleviate tau pathology and associated neurodegeneration offering an alternative therapeutic strategy to kinase and aggregation inhibitors in tauopathies (Yuzwa et al., 2008; Yuzwa et al., 2012; Yuzwa et al., 2014b; Graham et al., 2014; Hastings et al., 2017; Lee et al., 2021).